Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.49 |
| ▸ | CNR2 | P34972 | 12/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 3/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284028 | 0.95 | CNR1 (0.55) | CNR1CNR2KDM4ETLR8 | |
| SCHEMBL283910 | 0.89 | KDM4E (0.44) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL15007149 | 0.85 | CNR1 (0.42) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL27667658 | 0.85 | LMNA (0.40) | CNR1CNR2TLR8NR1H3 | |
| SCHEMBL284110 | 0.82 | CNR1 (0.40) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL283715 | 0.82 | KDM4E (0.39) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL3843249 | 0.82 | KDM4E (0.46) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL1924672 | 0.81 | KDM4E (0.42) | CNR1CNR2KDM4EGRNSORT1 | |
| SCHEMBL10625859 | 0.80 | CNR1 (0.41) | CNR1CNR2TLR8 | |
| SCHEMBL23399829 | 0.79 | CNR1 (0.52) | CNR1CNR2KDM4EGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2411371-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2411370-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8288428-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-10-16 | — | — | US | disclosed |
| US-8236822-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2411370-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411371-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010111574-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249086-A1 | Compounds As Cannabinoid Receptor Ligands | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111573-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR1 1/4885CNR2 2/4885KDM4E 1649/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR1 1/4885CNR2 2/4885KDM4E 1649/4885 |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 2286/4885 |
| US-20100249086-A1 | Compounds As Cannabinoid Receptor Ligands | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.